NEW YORK (GenomeWeb News) – Sequenom shareholders this week filed suit against the company and several individual current and former executives in relation to the company's mishandling of data surrounding its non-invasive test for fetal gene and chromosome abnormalities.

The complaint, filed Monday in the US District Court for the Southern District of California, alleges breach of fiduciary duties against a number of current and ex-officials, and levels charges of insider stock trading against one of the former officials.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.